Biocon Pharma Limited subsidiary received Health Canada approval for Micafungin for Injection, USP, 50 mg and 100 mg.
The product is indicated for treatment of Candidemia, Candida Peritonitis, and prophylaxis of Candida infections.
Approval strengthens Biocon's integrated biosimilars and generics portfolio according to company statement.